ナノプラットフォームによる代謝再プログラムにより,抗腫瘍療法における抵抗メカニズムを克服する
Xin-Xin Lu1, Jiao-Jiao Yang1, Fan Gao1
1Institute of Advanced Materials and Flexible Electronics (IAMFE), School of Chemistry and Materials Science, Nanjing University of Information Science & Technology, Nanjing, 210044, China. gaofan@nuist.edu.cn.
Journal of materials chemistry. B
|February 19, 2026
まとめ
ナノ粒子は,治療抵抗を克服するために腫瘍代謝を再プログラムすることができます. この戦略は,治療の効果を高め,副作用を軽減し,がん治療の成果を向上させます.
科学分野:
- 腫瘍学 腫瘍学
- ナノテクノロジー ナノテクノロジー
- メタボリックエンジニアリング
背景:
- 治療抵抗性は,がん治療における重要な課題である.
- 腫瘍は,治療を生き延び,増殖するために,変化した代謝を利用します.
- 代謝再プログラミングは,腫瘍を治療に敏感にするための有望な戦略です.
研究 の 目的:
- ナノプラットフォームによる代謝再プログラミングの枠組みを提示する.
- 多様な腫瘍耐性メカニズムを逆転させるための戦略を統一する.
- 腫瘍を様々な治療法に敏感にするためのナノプラットフォームを強調する.
主な方法:
- ナノプラットフォームベースの戦略の体系的なレビュー.
- 重要な代謝経路を調節するナノプラットフォームの分析.
- メタボリック介入とコントロールされた出産の統合.
主要な成果:
- ナノプラットフォームは精密に代謝経路を調節し,化学療法,熱療法,ROSベースの治療,免疫療法を強化します.
- これらのプラットフォームは,治療効果と選択性を改善します.
- システム毒性の低下は,ナノプラットフォームの適用で観察されています.
結論:
- ナノプラットフォームによる代謝再プログラミングは,腫瘍抵抗に対する有効な戦略です.
- 課題には,代謝異質性,生物安全性,臨床翻訳が含まれています.
- 将来の研究は,トランスレーション性がん治療のための合理的なナノプラットフォーム設計に焦点を当てるべきです.
関連する概念動画
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Electron Transport Chain: Complex I and II
19.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.1K


